Johnson & Johnson’s stay-out-of-jail marketing for schizophrenia blockbuster Invega Sustenna raises eyebrows

The FDA recently approved new language for the label of J&J's 9-year-old schizophrenia treatment, Invega Sustenna, stating that the drug can delay the arrest or incarceration of patients taking it. Now some mental health experts are questioning whether allowing J&J to market a drug for that purpose is really a good idea.Original Article